THERAPY DOSSIER · th-52f8db43bacb

Hydroxysafflor yellow A, an active ingredient of Carthamus tinctorius L.

Nutraceutical

Evidence & regulatory context

Mechanism: Not recorded
Target: Not recorded
Injury models: Chemical/toxin
Reported indication: Not recorded
First approval: Not recorded
Development stage: Not recorded
ChEMBL record: Not recorded
ChEMBL max phase: Not recorded
Synonyms: Not recorded
Note: Not recorded

Clinical trials 0

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

No linked human trial in this dataset.

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 29294256 ↗2018Reported benefit

Protective effect of hydroxysafflor yellow A on bleomycin-induced pulmonary inflammation and fibrosis in rats.

RatChemical/toxinWistarn = n=8 or 12 per group across 6 groupsIntraperitoneal35.6, 53.3 and 80.0 mg/kg/dayCommenced after bleomycin administration

Model: Bleomycin-induced acute lung inflammation and chronic pulmonary fibrosis

Hydroxysafflor yellow A ameliorated lung inflammation at day 7 and fibrosis at day 21, raised PaO2 and lowered PaCO2, and reduced TNF-alpha, IL-1beta and IL-6 mRNA and NF-kappaB p65-positive cell numbers at 53.3 and 80.0 mg/kg. At the same doses it attenuated the increases in TGF-beta1, alpha-SMA a…

Extraction: extract · Supplied extraction confidence: 0.8. Machine-extracted fields require source verification.

Loading the evidence…